{
    "nctId": "NCT04187898",
    "briefTitle": "Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer",
    "officialTitle": "Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients With Breast-Cancer Receiving Docetaxel and Cyclophosphamide",
    "overallStatus": "COMPLETED",
    "conditions": "Neutropenia, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 59,
    "primaryOutcomeMeasure": "Time to Recovery of Absolute Neutrophil Count (ANC) From Nadir to \u22651.5\u00d710^9/L in Cycle 1",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Willing and capable of giving written Informed Consent and able to adhere to study drug dosing time and blood draw schedules\n* New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer\n* Candidate to receive adjuvant or neoadjuvant TC chemotherapy\n* Age must be at least 18 years for the Early Phase, and between 18 to \u226455 years for the Expansion Phase\n* ANC \u22651.5\u00d710\\^9/liter (L).\n* Platelet count \u2265100\u00d710\\^9/liter (L).\n* Hemoglobin \\>10 grams per deciliter (g/dL).\n* Calculated creatinine clearance \\>50 milliliter per minute (mL/min).\n* Total bilirubin \u22641.5 milligrams per deciliter (mg/dL).\n* Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) \u22642.5\u00d7upper limit of normal (ULN).\n* Alkaline phosphatase \u22642.0\u00d7ULN.\n* Eastern Cooperative Oncology Group (ECOG) \u22642\n* Willing to practice 2 forms of contraceptives (1 must be a barrier method), from study entry through 30 days after last dose of study drug/ early discontinuation\n* Negative urine pregnancy test within 30 days before randomization\n\nExclusion Criteria:\n\n* Active concurrent malignancy (except non melanoma skin cancer or carcinoma in situ of the cervix) or life-threatening disease\n* Known sensitivity to Escherichia coli (E. coli) derived products\n* Concurrent adjuvant cancer therapy other than the trial-specified therapies\n* Locally recurrent/metastatic breast cancer\n* Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development within 3 months prior to the administration of study drug\n* Receiving anti-infectives, has an underlying medical condition or other serious illness that would impair the ability to receive protocol-specified treatment\n* Used any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study\n* Prior bone marrow or stem cell transplant\n* Prior radiation therapy within 30 days prior to enrollment\n* Major surgery within 30 days prior to enrollment\n* Pregnant or breastfeeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT"
}